XML 50 R33.htm IDEA: XBRL DOCUMENT v3.19.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2018
Stockholders' Equity Note [Abstract]  
Schedule of stock options activity
   Number of options   Weighted average exercise price  

Weighted average remaining contractual term

(in years)

   Aggregate intrinsic value 
                 
Outstanding as of January 1, 2018   679,552   $13.20    3.35   $4,517 
Granted   -    -           
Exercised   (215,542)   9.87           
Expired and forfeited   (48,500)   15.76           
                     
Outstanding as of December 31, 2018   415,510   $14.62    2.69   $3 
                     
Vested and expected to vest at December 31, 2018   415,510   $14.62    2.69   $3 
                     
Exercisable as of December 31, 2018   159,058   $11.81    2.02   $3 
Schedule of stock options under 2013 share option plan
  

Options outstanding

at December 31, 2018

 

Options exercisable

at December 31, 2018

Exercise price  Number outstanding   Weighted average exercise price  Weighted average remaining contractual life  Number exercisable   Weighted average exercise price  Weighted average remaining contractual life
$       $  In years       $  In years
                       
6.00   2,250   6.00  0.56   2,250   6.00  0.56
11.12-14.52   259,558   11.86  2.22   156,808   11.89  2.05
18.90-19.85   153,702   19.42  3.52   -   -  -
                       
    415,510          159,058       
Schedule of RSUs activity
   Number of RSUs  

Weighted average remaining contractual term

(in years)

   Aggregate intrinsic value 
             
Outstanding as of January 1, 2018   240,054    1.74   $4,765 
Granted   32,700           
Vested   (74,210)          
Cancelled   (29,675)          
                
Outstanding as of December 31, 2018   168,869    1.40   $1,253 
                
Vested and expected to vest as of December 31, 2018
   168,869    1.40   $1,253 
Schedule of departmental allocation of share-based compensation charge
  Year ended December 31, 
   2018(*)   2017(*)   2016(*) 
             
Cost of revenues  $112   $189   $118 
Research and development, net   808    473    625 
Sales and marketing, net   698    499    199 
General and administrative   503    1,055    1,529 
                
   $2,121   $2,216   $2,471 

 

(*)Including $1,359, $1,335 and $1,331 of compensation cost related to RSUs for the year ended December 31, 2018, 2017 and 2016, respectively.